Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

2.50
Hdl Handle:
http://hdl.handle.net/10541/78228
Title:
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Authors:
Fogelman, I; Blake, G M; Blamey, R; Palmer, Michael K; Sauerbrei, W; Schumacher, M; Serin, D; Stewart, Alan L; Wilpshaar, W
Abstract:
The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment. In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years. At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were -10.5% and -6.5% ( P=0.0005) for lumbar spine and -6.4% and -4.5% ( P=0.04) for femoral neck, respectively. At 3 years, partial recovery of BMD was observed in goserelin recipients. In contrast, mean BMD losses for the CMF group indicated persistent BMD loss. No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck. In the CMF group, based on amenorrhea status at 48 weeks, BMD losses at the lumbar spine were greater for amenorrheic than non-amenorrheic patients. Ovarian suppression resulting in amenorrhea was closely related to BMD loss in both treatment groups. Overall, patients who received CMF did not show recovery of BMD throughout follow-up, whereas partial recovery was observed 1 year after cessation of goserelin therapy, associated with the return of ovarian function in the majority of patients.
Affiliation:
Department of Nuclear Medicine, Guy's, Kings and St Thomas' Hospital Medical School, SE1 9RT, London, UK. ignac.fogelman@kcl.ac.uk
Citation:
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). 2003, 14 (12):1001-6 Osteoporos Int
Journal:
Osteoporosis International
Issue Date:
Dec-2003
URI:
http://hdl.handle.net/10541/78228
DOI:
10.1007/s00198-003-1508-y
PubMed ID:
14530912
Type:
Article
Language:
en
ISSN:
0937-941X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFogelman, I-
dc.contributor.authorBlake, G M-
dc.contributor.authorBlamey, R-
dc.contributor.authorPalmer, Michael K-
dc.contributor.authorSauerbrei, W-
dc.contributor.authorSchumacher, M-
dc.contributor.authorSerin, D-
dc.contributor.authorStewart, Alan L-
dc.contributor.authorWilpshaar, W-
dc.date.accessioned2009-08-21T14:33:34Z-
dc.date.available2009-08-21T14:33:34Z-
dc.date.issued2003-12-
dc.identifier.citationBone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). 2003, 14 (12):1001-6 Osteoporos Inten
dc.identifier.issn0937-941X-
dc.identifier.pmid14530912-
dc.identifier.doi10.1007/s00198-003-1508-y-
dc.identifier.urihttp://hdl.handle.net/10541/78228-
dc.description.abstractThe purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment. In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years. At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were -10.5% and -6.5% ( P=0.0005) for lumbar spine and -6.4% and -4.5% ( P=0.04) for femoral neck, respectively. At 3 years, partial recovery of BMD was observed in goserelin recipients. In contrast, mean BMD losses for the CMF group indicated persistent BMD loss. No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck. In the CMF group, based on amenorrhea status at 48 weeks, BMD losses at the lumbar spine were greater for amenorrheic than non-amenorrheic patients. Ovarian suppression resulting in amenorrhea was closely related to BMD loss in both treatment groups. Overall, patients who received CMF did not show recovery of BMD throughout follow-up, whereas partial recovery was observed 1 year after cessation of goserelin therapy, associated with the return of ovarian function in the majority of patients.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAmenorrhea-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Density-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshFemur Neck-
dc.subject.meshFluorouracil-
dc.subject.meshGoserelin-
dc.subject.meshHumans-
dc.subject.meshLumbar Vertebrae-
dc.subject.meshMethotrexate-
dc.subject.meshPremenopause-
dc.titleBone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).en
dc.typeArticleen
dc.contributor.departmentDepartment of Nuclear Medicine, Guy's, Kings and St Thomas' Hospital Medical School, SE1 9RT, London, UK. ignac.fogelman@kcl.ac.uken
dc.identifier.journalOsteoporosis Internationalen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.